SELENOW

Across TCGA pan-cancer cohorts, SELENOW mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SELENOW data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SELENOW mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SELENOW expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

UCEC, GBM, and LSCC are the cancer types where SELENOW mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.647	1.000	.017	4	view →
GBM	DFS	Tertile	All	0.223	0.490	.025	4	view →
LSCC	DFS	Median	All	0.892	1.000	.024	3	view →
PDAC	OS	Tertile	IV	0.916	0.231	.024	3	view →
CCRCC	DFS	Median	All	0.646	0.832	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SELENOW–UCEC (OS)

Open the UCEC breakdown →